free counter

EC Healthcare Chairman Mr. Eddy Tang Further Increases Shareholding, Exhibiting Unwavering Assurance later on Development of the Group

HONG KONG, Sept 9, 2022 – (ACN Newswire) – EC Healthcare (the “Company”, which as well as its subsidiaries is known as the “Group”, SEHK stock code: 2138), the biggest non-hospital medical group in Hong Kong*, is very happy to announce that on 7 September 2022, the Group’s Chairman, Executive Director and CEO Mr. Tang Chi Fai further acquired a complete of 170,000 shares of the business on the open market for about HK$854,800 at the average price of HK$5.0282 per share. Ahead of this transaction, Mr. Tang had already increased his shareholding in the business earlier this month on 1 September 2022, acquiring a complete of 107,000 shares at the average price of $5.4905 per share. Following the transaction, Mr. Tang holds an aggregate of 722,204,610 shares in the business, increasing his equity stake from 61.27% to 61.29%.

Mr. Eddy Tang, Chairman, Executive Director and CEO of EC Healthcare said, “Regardless of the current financial state, we have been confident that the medical market will stay resilient and that long-term public-private healthcare partnerships will continue steadily to drive up investment in Hong Kong’s private healthcare sector. Reaping the huge benefits from its ongoing investments in elevating healthcare service offerings, the Group exemplified solid business recovery by delivering first-quarter sales level of a minimum of HK$860 million for the financial year that concluded on March 31, 2023. Management continues to be nevertheless upbeat concerning the Group’s business success in the years ahead. To be able to continue enhancing EC Healthcare’s enclosed healthcare ecosystem, the Group will move forward using its close collaboration with the major players in the technology, telecommunications, insurance, property, and pharmaceutical industries.”

About EC Healthcare

EC Healthcare is Hong Kong’s largest non-hospital medical service provider*, leveraging its core businesses of preventive and precision medicine, and focused on developing medical artificial intelligence by integrating its multi-disciplinary medical services. The move, that is supported by the Group’s high-end branding and quality customer services, is targeted at offering customers effective and safe healthcare and medical services with professionalism.

The Group principally partcipates in the provision of one-stop medical and healthcare services in Greater China. The Group offers a full selection of products under its well-known brands, including those of its one-stop aesthetic medical solutions provider DR REBORN which includes ranked first in Hong Kong by sales for a long time, primary care clinics jointly established with Tencent Doctorwork, chiropractic services centre NY Spine and Physiotherapy Center NYMG, health management centre re:HEALTH, a vaccine centre Hong Kong Professional Vaccine HKPV, a thorough dental centre EC DENTAL HYGIENE, a diagnostic and imaging centre HKAI, an oncology treatment centre reVIVE, each day procedure centre HKMED, a specialty clinic SPECIALISTS CENTRAL, NEW INFIRMARY and Prime Medical Centres, obstetrics and gynaecology specialist ZENITH INFIRMARY AND PRENATAL DIAGNOSIS CENTRE, specialists central, a paediatric center PRIME CARE, cardiology center HONG KONG INTERNATIONAL CARDIOLOGY CENTER, PathLab Medical Laboratories, a specialist hair care center HAIR FOREST, Ophthalmology Center VIVID EYE and EC Veterinary Hospital and Imaging Center.

*According to independent research conducted by Frost and Sullivan when it comes to revenue in 2020 and 2021

Topic:News release summary

Source: EC Healthcare

Sectors:BioTech, Healthcare & Pharm

From the Asia Corporate News Network

Copyright 2022 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

Read More

Related Articles

Leave a Reply

Your email address will not be published.

Back to top button

Adblock Detected

Please consider supporting us by disabling your ad blocker